138 related articles for article (PubMed ID: 29077206)
1. Population Pharmacokinetics of Intravenous Busulfan in Japanese Pediatric Patients With Primary Immunodeficiency Diseases.
Ishiwata Y; Nagata M; Tsuge K; Takahashi H; Suzuki S; Imai K; Takagi M; Kanegane H; Morio T; Yasuhara M
J Clin Pharmacol; 2018 Mar; 58(3):327-331. PubMed ID: 29077206
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
Cremers S; Schoemaker R; Bredius R; den Hartigh J; Ball L; Twiss I; Vermeij P; Vossen J
Br J Clin Pharmacol; 2002 Apr; 53(4):386-9. PubMed ID: 11966670
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation.
Nakamura H; Sato T; Okada K; Miura G; Ariyoshi N; Nakazawa K; Kitada M
Ther Drug Monit; 2008 Feb; 30(1):75-83. PubMed ID: 18223466
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
[TBL] [Abstract][Full Text] [Related]
5. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
[TBL] [Abstract][Full Text] [Related]
7. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Fisher VL; Barnes YJ; Nuss SL
Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation.
Wu X; Xie H; Lin W; Yang T; Li N; Lin S; Yuan X; Ren J; Li X; Huang X
Clin Exp Pharmacol Physiol; 2017 May; 44(5):529-538. PubMed ID: 28135768
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
[TBL] [Abstract][Full Text] [Related]
11. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.
Nishikawa T; Yamaguchi H; Ikawa K; Nakayama K; Higashi E; Miyahara E; Abematsu T; Nakagawa S; Kodama Y; Tanabe T; Shigemi A; Shinkoda Y; Okamoto Y; Takeda Y; Kawano Y
Pediatr Int; 2019 Jun; 61(6):558-565. PubMed ID: 30963629
[TBL] [Abstract][Full Text] [Related]
12. Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
Neroutsos E; Athanasiadou I; Paisiou A; Zisaki K; Goussetis E; Archontaki H; Tsirigotis P; Kitra M; Grafakos S; Spyridonidis A; Dokoumetzidis A; Valsami G
J Pharm Pharmacol; 2021 Sep; 73(10):1340-1350. PubMed ID: 34244783
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation.
Sato M; Kako S; Matsumoto K; Oshima K; Akahoshi Y; Nakano H; Ugai T; Yamasaki R; Wada H; Ishihara Y; Sakamoto K; Kawamura K; Ashizawa M; Terasako-Saito K; Kimura S; Nakasone H; Kikuchi M; Tanihara A; Yamazaki R; Tanaka Y; Kanda J; Nishida J; Morita K; Kanda Y
Int J Hematol; 2015 May; 101(5):497-504. PubMed ID: 25672602
[TBL] [Abstract][Full Text] [Related]
14. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation.
Bostrom B; Enockson K; Johnson A; Bruns A; Blazar B
Pediatr Transplant; 2003; 7 Suppl 3():12-8. PubMed ID: 12603688
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Schuler US; Ehrsam M; Schneider A; Schmidt H; Deeg J; Ehninger G
Bone Marrow Transplant; 1998 Aug; 22(3):241-4. PubMed ID: 9720736
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.
Takamatsu Y; Sasaki N; Ogata K; Yukawa E; Jimi S; Hara S; Tamura K
Cancer Chemother Pharmacol; 2010 May; 65(6):1203-7. PubMed ID: 20169347
[TBL] [Abstract][Full Text] [Related]
17. Predictive performance of a busulfan pharmacokinetic model in children and young adults.
Bartelink IH; van Kesteren C; Boelens JJ; Egberts TC; Bierings MB; Cuvelier GD; Wynn RF; Slatter MA; Chiesa R; Danhof M; Knibbe CA
Ther Drug Monit; 2012 Oct; 34(5):574-83. PubMed ID: 22972539
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Analysis of Busulfan in Japanese Pediatric and Adult HCT Patients.
Kawazoe A; Funaki T; Kim S
J Clin Pharmacol; 2018 Sep; 58(9):1196-1204. PubMed ID: 29663421
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and early complications of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation.
Pakakasama S; Chuansumrit A; Damkong B; Sirachainan N; Sirireung S; Hongeng S
Hematol Oncol Stem Cell Ther; 2008; 1(3):189-92. PubMed ID: 20063551
[No Abstract] [Full Text] [Related]
20. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.
Danielak D; Twardosz J; Kasprzyk A; Wachowiak J; Kałwak K; Główka F
Eur J Clin Pharmacol; 2018 Jan; 74(1):79-89. PubMed ID: 28975382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
